Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG

Inclusion Criteria: * Patients who have been treated or not treated with hypertension from 20 to 80 years of age * Patients with electrocardiographic left ventricular hypertrophy (In this study, we define left ventricular hypertrophy if one of the following two criteria is met) 1. RaVL+SV3 \> 20mm(M). 16mm(F) 2. SV1+RV5 or RV6 \> 35mm. * Patients who are taking or expecting Fimasartan Exclusion Criteria: * Patients with unstable angina or myocardial infarction within 3 months * Patients with clinically significant severe valve disease, congenital heart disease, peripheral vascular disease, cerebrovascular disease * Clinically significant severe congestive heart failure patients * Patients with renal dialysis * Clinically significant renal disease patients * Patients with clinically significant hepatic impairment * Patients with a history of alcohol or substance abuse * Patients with hypersensitivity to angiotensin-receptor blocker * Patients needing angiotensin-receptor blocker drugs other than fimasartan * For women, pregnancy, Patients who are breastfeeding or planning to become pregnant * A person who is determined to be inappropriate by the Investigator * Patients participating in other clinical trials